Newsroom Bayer

November
22,
2022
| 14:00 PM Europe/Amsterdam

Bayer advances Radiology development portfolio and fosters innovation in AI

Not intended for U.S. and UK Media - Radiological Society of North America (RSNA) 2022 Annual Meeting

New clinical data for the development compound gadoquatrane, a novel MRI contrast agent, presented at RSNA 2022 / Three new partnerships, AI app accelerator program and pipeline updates to be featured / Collaboration agreements signed to expand
November
11,
2022
| 14:52 PM Europe/Amsterdam
Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT / Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness / Bayer will apply for a patent term extension for the
November
10,
2022
| 08:59 AM Europe/Amsterdam
Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix
November
09,
2022
| 13:30 PM Europe/Amsterdam
San Diego – November 9, 2022 – Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune
November
08,
2022
| 10:01 AM Europe/Amsterdam
.
November
08,
2022
| 07:30 AM Europe/Amsterdam
Group sales increase by 5.7 percent (Fx & portfolio adj.) to 11.281 billion euros  / EBITDA before special items rises by 17.3 percent to 2.451 billion euros / Crop Science achieves strong sales gains – sales also up at Pharmaceuticals and Consumer
November
05,
2022
| 06:59 AM Europe/Amsterdam

Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16

Not intended for U.S. and UK Media – Aflibercept 8 mg late-breaking data at the 55th Annual Scientific Meeting 2022 of the Retina Society:

Aflibercept 8 mg maintained 16-week dosing intervals in up to 89% of patients with as few as 5 injections until week 48 / Aflibercept 8 mg demonstrated non-inferior vision gains to Eylea (aflibercept 2 mg) with 83% of patients with neovascular (wet)
November
03,
2022
| 13:59 PM Europe/Amsterdam
California-based NuCicer has developed chickpeas with 75 percent more protein than conventional varieties, unlocking the potential of chickpea protein to become a scalable, affordable foundation for a sustainable plant-based future  / NuCicer’s
October
26,
2022
| 12:00 PM Europe/Amsterdam
FIDELITY: Late-breaking data from pooled, post-hoc analysis will provide new insights into the efficacy and safety of Kerendia in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) who have sustained an acute change in estimated
October
26,
2022
| 09:00 AM Europe/Amsterdam
The newest LifeHub in the Bayer network will connect the company more closely to the German innovation ecosystem of scientists, researchers, decision makers, and entrepreneurs / Focus lies on dialogue and innovation through open approaches that
October
25,
2022
| 08:28 AM Europe/Amsterdam

Bayer to present latest research on real-world impact of menopause symptoms at IMS 2022

Not intended for U.S. and UK Media – 18th World Congress on Menopause by the International Menopause Society (IMS):

The REALISE study explored symptom burden and impact of menopause symptoms in women across multiple countries, and the views of their treating physicians.  / This study confirmed vasomotor symptoms (VMS) are considered the most common and

Sign up for our Newsletter

We will keep you informed about the latest news.